These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11224745)

  • 1. New developments in the management of cytomegalovirus infection and disease after renal transplantation.
    Kletzmayr J; Kreuzwieser E; Klauser R
    Curr Opin Urol; 2001 Mar; 11(2):153-8. PubMed ID: 11224745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
    Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
    Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
    Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
    Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
    Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H; Kanz L; Jahn G; Einsele H
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
    Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
    Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.
    Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F
    J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
    Reischig T; Kacer M; Hruba P; Jindra P; Hes O; Lysak D; Bouda M; Viklicky O
    Antivir Ther; 2017; 22(6):503-513. PubMed ID: 28091392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function.
    Geddes CC; Church CC; Collidge T; McCruden EA; Gillespie G; Matthews E; Hainmueller A; Briggs JD
    Nephrol Dial Transplant; 2003 Sep; 18(9):1891-8. PubMed ID: 12937240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
    Conti DJ; Freed BM; Singh TP; Gallichio M; Gruber SA; Lempert N
    Arch Surg; 1995 Nov; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.